Morgan Stanley upgrades Sanofi stock rating to Overweight on growth outlook

Morgan Stanley upgraded Sanofi (SNY) to Overweight with a $58.00 price target, citing confidence in the company's return to organic growth and margin expansion, underpinned by strong recent revenue and gross profit performance. The firm anticipates well-supported 2025 earnings growth, driven by Amvuttra royalty streams and share buybacks, projecting continued sales momentum into 2026 despite some anticipated 2027 margin contraction. This positive outlook is echoed by Jefferies' reiterated Buy rating, though BofA Securities recently adjusted its price target following mixed trial results, emphasizing upcoming pipeline readouts.

Analysis

Sanofi (SNY) received a significant vote of confidence from Morgan Stanley, which upgraded the stock to Overweight from Equalweight and raised its price target to $58.00 from $56.00. The upgrade is predicated on a return to organic growth and margin improvement, supported by strong recent performance, including 15.65% revenue growth and a 71.32% gross profit margin over the last twelve months. Morgan Stanley's 2025 outlook is constructive, anticipating earnings growth driven by a share buyback program and the Amvuttra royalty stream, which could lead to a guidance upgrade in Q3 2025. Projections for 2026 are also robust, with 8% year-over-year sales momentum forecasted, alongside an estimated €830 million in royalty income from Alnylam’s Amvuttra, suggesting margin expansion to 29.6%. While a 30 basis point margin contraction is expected in 2027, Morgan Stanley views market concerns as excessive, believing the Amvuttra royalty stream will provide a stronger-than-expected operating profit boost. This contrasts slightly with BofA Securities, which maintained a Buy rating but lowered its price target following mixed Phase III trial results for itepekimab, underscoring the importance of upcoming Phase III data for amlitelimab. Jefferies, however, reiterated its Buy rating, highlighting a favorable safety profile for one of its treatments. The current valuation at $46.50, combined with a 3.44% dividend yield, positions the stock as potentially undervalued, according to InvestingPro analysis.

Key Decisions for Investors

• Given the Morgan Stanley upgrade, strong fundamentals, and a significant gap between the current price and the $58.00 target, investors may consider the current valuation an attractive entry point for a long position.
• It is critical to monitor upcoming clinical trial catalysts, particularly the Phase III results for amlitelimab expected in the third quarter, as pipeline execution remains a key variable influencing analyst ratings and stock performance.
• While the long-term margin outlook appears solid, investors should track the performance of the Amvuttra royalty stream to ensure it can sufficiently offset the anticipated €800 million loss of refunding income in 2027.
• For income-oriented portfolios, the 3.44% dividend yield, backed by a share buyback program and a 'GOOD' financial health score, offers a compelling total return profile that could cushion against pipeline-related volatility.